

- (12) Appendix F containing U.S. Patent No. 6,277,375; and
(13) Appendix G containing Zuckier et al., "Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life," *Cancer Research* (1998), 58(17):3905-3508.

IN THE CLAIMS:

Please cancel claims 12 - 43 without prejudice to applicants' prosecuting claims of identical or similar scope in one or more divisional or continuation applications.

Please add the following new claims 44 - 51:

44. (new) A method of extending the serum half-life of an antibody having a first moiety capable of binding to FcRb receptor, the method comprising:

linking to said antibody at least a second moiety capable of binding to FcRb receptor in a pH-dependent manner, wherein said antibody binds FcRb receptor with greater avidity at pH 7.4 after said linking.

C1 45. (new) The method of claim 44, wherein any one of said first or at least second moieties comprises an immunoglobulin Fc region.

46. (new) The method of claim 44 wherein any one of said first or at least second moieties comprises a region consisting of an immunoglobulin hinge-CH2-CH3.

47. (new) The method of claim 44 wherein any one of said first or at least second moieties comprises a region consisting of an immunoglobulin CH2-CH3.

48. (new) An antibody with extended serum half-life, produced by the method of any one of claims 44 - 47.

49. (new) An antibody with an extended serum half-life, said antibody comprising:

a first moiety capable of binding FcRb receptor; and
at least a second moiety capable of binding FcRb receptor,

C1 wherein said at least second moiety confers upon said antibody avidity of binding FcRb receptor at pH 7.4 greater than that of said antibody lacking said at least second moiety;

wherein said at least second moiety binds FcRb receptor in a pH dependent manner, and

wherein said at least second moiety comprises an immunoglobulin CH3 region that contributes to FcRb receptor binding.

50. (new) The antibody of claim 49 wherein said second moiety further comprises an immunoglobulin CH2 region.

51. (new) The antibody of claim 50 wherein said second moiety further comprises an immunoglobulin hinge region.
